Zobrazeno 1 - 10
of 65
pro vyhledávání: '"Andrew A. Vernon"'
Autor:
Christian Lienhardt, Andrew Nunn, Richard Chaisson, Andrew A Vernon, Matteo Zignol, Payam Nahid, Eric Delaporte, Tereza Kasaeva
Publikováno v:
PLoS Medicine, Vol 17, Iss 2, p e1003059 (2020)
Christian Lienhardt and co-authors discuss the conclusions of the PLOS Medicine Collection on advances in clinical trial design for development of new tuberculosis treatments.
Externí odkaz:
https://doaj.org/article/fab657c1693c4bcd986269f2a1b9ef06
Publikováno v:
PLoS Medicine, Vol 16, Iss 9, p e1002915 (2019)
Christian Lienhardt and colleagues discuss the importance of communication and coordination between regulators, researchers, and policy makers to ensure tuberculosis trials provide high-quality evidence for policy decisions.
Externí odkaz:
https://doaj.org/article/ab082010efd343748221e3584cb13c29
Autor:
Andrew, Ray Vernon
MA (English), North-West University, Potchefstroom Campus "No abstract" Masters
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______1399::4c817e23eef860a4c19b6f45faa2d244
https://hdl.handle.net/10394/39037
https://hdl.handle.net/10394/39037
Autor:
Rokeya Tasneen, Andrew Garcia, Paul J. Converse, Matthew D. Zimmerman, Veronique Dartois, Ekaterina Kurbatova, Andrew A. Vernon, Wendy Carr, Jason E. Stout, Kelly E. Dooley, Eric L. Nuermberger
Publikováno v:
Antimicrob Agents Chemother
A recent landmark trial showed a 4-month regimen of rifapentine, pyrazinamide, moxifloxacin and isoniazid (PZMH) to be non-inferior to the 6-month standard of care. Here, two murine models of tuberculosis were used to test whether novel regimens repl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f7b7c3fae04516a99811ea557656ecc0
https://pubmed.ncbi.nlm.nih.gov/35315690
https://pubmed.ncbi.nlm.nih.gov/35315690
Autor:
William J Burman, Mark F Cotton, Diana M Gibb, A Sarah Walker, Andrew A Vernon, Peter R Donald
Publikováno v:
PLoS Medicine, Vol 5, Iss 8, p e176 (2008)
Externí odkaz:
https://doaj.org/article/c8be7243c66444589108fe9aeddd9c22
Autor:
Ian M Rosenthal, Ming Zhang, Kathy N Williams, Charles A Peloquin, Sandeep Tyagi, Andrew A Vernon, William R Bishai, Richard E Chaisson, Jacques H Grosset, Eric L Nuermberger
Publikováno v:
PLoS Medicine, Vol 4, Iss 12, p e344 (2007)
Availability of an ultra-short-course drug regimen capable of curing patients with tuberculosis in 2 to 3 mo would significantly improve global control efforts. Because immediate prospects for novel treatment-shortening drugs remain uncertain, we exa
Externí odkaz:
https://doaj.org/article/b9fa516ad9b1418093488e15f77366b4
Autor:
Andrew A. Vernon, M. Elsa Villarino
Publikováno v:
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 54(6)
Through analytic synthesis of data from observational cohorts of healthcare providers from the 1920s through the 1950s, we estimate that individuals with latent tuberculosis have a 79% lower risk of tuberculosis disease following reinfection compared
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ab61267520694e5795f1711feee19999
https://pubmed.ncbi.nlm.nih.gov/22267721
https://pubmed.ncbi.nlm.nih.gov/22267721
Autor:
Andrew A. Vernon
Therapy of tuberculosis has been hailed as one of the great achievements of the mid-20th century. The remarkable efficacy of shortcourse chemotherapy (SCC) as developed by the British Medical Research Council and others is now well established. Howev
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::46b261955137fae39d8aecea93f46fd8
https://doi.org/10.1159/000330479
https://doi.org/10.1159/000330479
Autor:
Jacques H. Grosset, Andrew N. Vernon, Eric L. Nuermberger, William R. Bishai, Tetsuyuki Yoshimatsu, Richard E. Chaisson, Sandeep Tyagi, Richard J. O'Brien
Publikováno v:
American journal of respiratory and critical care medicine. 169(3)
Tuberculosis continues to be a major cause of morbidity and mortality in the world. The expansion of tuberculosis control programs has been limited by the lengthy and cumbersome nature of current chemotherapeutic regimens. A new drug that improves th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2de11f5a839aff8169efc7db4c63ef2b
https://pubmed.ncbi.nlm.nih.gov/14739133
https://pubmed.ncbi.nlm.nih.gov/14739133
Autor:
Abdelhalim Bentoucha, Baohong Ji, Nacer Lounis, Chantal Truffot-Pernot, J. Grosset, Giorgio Roscigno, Richard J. O'Brien, Andrew N. Vernon
Publikováno v:
Antimicrobial agents and chemotherapy. 45(12)
Mice infected with 1.6 × 10 7 CFU of Mycobacterium tuberculosis were treated 14 days later for 6 months with a regimen of once-weekly 10 mg of rifapentine and 75 mg of isoniazid per kg of body weight supplemented with either 150 mg of streptomycin p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ced81a00d59caa3711f05e74276bf48a
https://pubmed.ncbi.nlm.nih.gov/11709328
https://pubmed.ncbi.nlm.nih.gov/11709328